Histamont-B Tablet is a combination medication containing Bilastine 20 mg and Montelukast 10 mg, indicated for the management of allergic conditions such as allergic rhinitis and chronic urticaria. Bilastine is a second-generation antihistamine that selectively antagonizes peripheral H1 histamine receptors, providing effective relief from symptoms like sneezing, nasal congestion, itching, and rhinorrhea without causing significant sedation. Montelukast is a leukotriene receptor antagonist that inhibits the cysteinyl leukotriene receptor, thereby reducing inflammation, bronchoconstriction, and mucus production associated with allergic responses. The synergistic action of these two agents offers comprehensive control of allergic symptoms by targeting multiple pathways involved in the allergic cascade. Histamont-B is typically administered orally once daily, with or without food, and is well tolerated with a low incidence of adverse effects. It is contraindicated in patients with known hypersensitivity to either component. Caution is advised in patients with hepatic impairment or a history of neuropsychiatric events. This combination therapy is particularly beneficial for patients requiring both antihistaminic and leukotriene receptor antagonist effects to achieve optimal symptom control. As with all medications, use under medical supervision is recommended to ensure safety and efficacy.